Lynne Powell
Direktor/Vorstandsmitglied bei BIORA THERAPEUTICS, INC.
Vermögen: 3 488 $ am 30.04.2024
Profil
Lynne M.
Powell is currently the Chief Executive Officer & Director at Tavanta Therapeutics, Inc. and an Independent Director at Biora Therapeutics, Inc. She was previously the Chief Executive Officer & Director at Druggability Technologies Holdings Ltd., Chief Commercial Officer & Senior Vice President at BioCryst Pharmaceuticals, Inc., and Senior VP-North American Commercial Operations at CSL Behring LLC.
Powell holds an MBA from Monash University and the University of Warwick, and an undergraduate degree from the University of East London.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIORA THERAPEUTICS, INC.
0,02% | 01.03.2024 | 5 746 ( 0,02% ) | 3 488 $ | 30.04.2024 |
Aktive Positionen von Lynne Powell
| Unternehmen | Position | Beginn |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.02.2019 |
Tavanta Therapeutics, Inc.
 Tavanta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tavanta Therapeutics, Inc. operates as a clinical-stage pharmaceutical company developing a diverse pipeline of specialty drugs. The company is based in King of Prussia, PA and has subsidiaries in Hungary. Lynne M. Powell has been the CEO of the company since 2019. | Vorstandsvorsitzender | 01.09.2019 |
Ehemalige bekannte Positionen von Lynne Powell
| Unternehmen | Position | Ende |
|---|---|---|
Druggability Technologies Holdings Ltd.
 Druggability Technologies Holdings Ltd. BiotechnologyHealth Technology Druggability Technologies Holdings Ltd., part of DRGT Holdco (Malta) Ltd., is a company headquartered in Dublin, Ireland. The firm develops proprietary drugs. | Vorstandsvorsitzender | 01.10.2019 |
| BIOCRYST PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2019 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Corporate Officer/Principal | 01.10.2014 |
Ausbildung von Lynne Powell
| Monash University | Masters Business Admin |
| University of Warwick | Masters Business Admin |
| University of East London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Private Unternehmen | 3 |
|---|---|
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
Druggability Technologies Holdings Ltd.
Druggability Technologies Holdings Ltd. BiotechnologyHealth Technology Druggability Technologies Holdings Ltd., part of DRGT Holdco (Malta) Ltd., is a company headquartered in Dublin, Ireland. The firm develops proprietary drugs. | Health Technology |
Tavanta Therapeutics, Inc.
Tavanta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tavanta Therapeutics, Inc. operates as a clinical-stage pharmaceutical company developing a diverse pipeline of specialty drugs. The company is based in King of Prussia, PA and has subsidiaries in Hungary. Lynne M. Powell has been the CEO of the company since 2019. | Health Technology |
